keyword
MENU ▼
Read by QxMD icon Read
search

Primary renal lymphoma

keyword
https://www.readbyqxmd.com/read/28352187/risk-of-subsequent-primary-malignancies-among-patients-with-prior-colorectal-cancer-a-population-based-cohort-study
#1
Jiao Yang, Shuting Li, Meng Lv, Yinying Wu, Zheling Chen, Yanwei Shen, Biyuan Wang, Ling Chen, Min Yi, Jin Yang
BACKGROUND: The site-distribution pattern and relative risk of subsequent primary malignancies (SPMs) in colorectal cancer (CRC) patients remains to be determined. MATERIALS AND METHODS: A population-based cohort of 288,390 CRC patients diagnosed between 1973 and 2012 from the Surveillance, Epidemiology, and End Results database was retrospectively reviewed. Standardized incidence ratios were calculated to estimate the relative risk for SPMs. RESULTS: The overall risk of SPMs increased in CRC patients (standardized incidence ratio 1...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28314541/risk-of-subsequent-primary-kidney-cancer-after-another-malignancy-a-population-based-study
#2
Omar Abdel-Rahman
BACKGROUND: Population-based data on the development of kidney cancer as a second malignant neoplasm following the diagnosis of other common malignancies are rare. This clinical scenario has been evaluated within the Surveillance, Epidemiology, and End Results (SEER) database. MATERIALS AND METHODS: The SEER-9 database (1973-2013) was queried using the SEER*Stat program to determine the standardized incidence ratios (SIRs) of kidney cancer development following each one of 10 common invasive malignancies (colorectal, breast, prostate, lung, thyroid, corpus uteri, urinary bladder, kidney/renal pelvis, cutaneous melanoma, and non-Hodgkin lymphoma)...
February 27, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28293043/treatment-of-post-transplantation-lymphoproliferative-disorders-after-kidney-transplant-with-rituximab-and-conversion-to-m-tor-inhibitor
#3
John Fredy Nieto-Rios, Sandra Milena Gómez de Los Ríos, Lina María Serna-Higuita, Catalina Ocampo-Kohn, Arbey Aristizabal-Alzate, Kenny Mauricio Gálvez-Cárdenas, Gustavo Adolfo Zuluaga-Valencia
BACKGROUND: Post-transplantation lymphoproliferative disorders are serious complications of organ transplantation which treatment is not yet standardized. OBJECTIVE: To describe the clinical response, overall and graft survival of patients in our center with this complication after kidney transplantation, which received rituximab as part of their treatment as well as conversion to m-TOR. METHODS: Retrospective study, which included patients, diagnosed with post-transplant lymphoproliferative disorders after kidney transplantation from January 2011 to July 2014...
December 30, 2016: Colombia Médica: CM
https://www.readbyqxmd.com/read/28263135/a-case-report-of-a-renal-diffuse-b-cell-lymphoma
#4
Raunak D Patel, Colton Walker, Daniel J Canter
Diffuse large B-cell lymphomas (DLBCL) are the most common lymphomas worldwide. They also appear to be the most common primary retroperitoneal lymphomas, but this presentation is relatively uncommon in the literature. Retroperitoneal masses, including lymphomas, often present with nonspecific symptoms and laboratory values, necessitating radiographic assessment and consideration of mass biopsy prior to the initiation of treatment. Here we present a case of a primary retroperitoneal DLBCL as well as a review of the clinical presentation, imaging findings, and differential diagnosis of such tumors...
February 2017: Canadian Journal of Urology
https://www.readbyqxmd.com/read/28122486/choice-of-induction-in-the-era-of-single-antigen-bead-testing-an-idiosyncratic-case-report
#5
Alexandre Hertig
Use of induction therapy after kidney transplant is based on immunologic risk status, but accurate assessment of risk in the era of advanced immunologic testing can be complex. Here, we describe the case of a young kidney recipient who had a Castleman disease, often regarded as a benign lymphoma. Our patient, a white male patient with Castleman disease, underwent a first kidney transplant with rabbit antithymocyte globulin induction but returned to dialysis after primary nonfunction occurred. A second donor became available who shared 3 class I HLA antigens with the first donor, but only low-level isolated donor-specific antibodies toward HLA-Cw were detected (mean fluorescence intensity < 1000)...
February 2017: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/28095016/renal-masses-detected-on-fdg-pet-ct-in-patients-with-lymphoma-imaging-features-differentiating-primary-renal-cell-carcinomas-from-renal-lymphomatous-involvement
#6
Carlos Nicolau, Evis Sala, Anita Kumar, Debra A Goldman, Heiko Schoder, Hedvig Hricak, Hebert Alberto Vargas
OBJECTIVE: The purpose of this study is to analyze the (18)F-FDG PET/CT features of solid renal masses detected in patients with lymphoma and to evaluate the ability of PET/CT to differentiate renal cell carcinoma (RCC) from renal lymphomatous involvement. MATERIALS AND METHODS: Thirty-six patients with solid renal masses on PET/CT performed for staging or follow-up of lymphoma were evaluated retrospectively. The features recorded for each renal mass included the following standardized uptake values (SUVs) on PET/CT: the maximum SUV (SUVmax), the mean SUV (SUVmean), the ratio of the SUVmax of the tumor to that of the normal kidney cortex, the ratio of the SUVmean of the tumor to that of the normal kidney cortex, the ratio of the SUVmax of the tumor to that of the normal liver, and the ratio of the SUVmean of the tumor to that of the normal liver...
April 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28090186/calcitriol-mediated-reversible-hypercalcemia-in-a-patient-with-primary-adrenal-lymphoma
#7
Shahnaz Ahmad Mir, Shariq Rashid Masoodi, Arshad Iqbal Wani, Syed Nisar Ahmad, Iqra Hameed
Primary adrenal lymphomas (PAL) are rare occurrences with only less than 150 cases reported in the literature. Two-thirds of these cases were reported in the last decade due to the advancements in imaging techniques and immunohistochemistry. The non-specific signs and symptoms have resulted in a delayed onset of symptoms and diagnosis of these tumors. Reports of the results of chemotherapy are not gratifying, and most patients die within one year of the diagnosis. We report a 65-year-old male with adrenal non-Hodgkin's lymphoma (NHL), who presented with hypercalcemia and renal failure...
November 2016: Malaysian Journal of Medical Sciences: MJMS
https://www.readbyqxmd.com/read/28056876/a-case-report-of-primary-unilateral-adrenal-nk-t-cell-lymphoma-good-clinical-outcome-with-trimodality-treatment
#8
Liu Hu, Weimin Xu, Mingwei Wang, Pan Wang, Guang Han, Chi Lin
BACKGROUND: Primary natural killer (NK)/T cell lymphoma of adrenal glands is an extremely rare tumor with aggressive clinical behavior. There have only been a few cases reported worldwide and the highest reported survival was 90 days. We report the first case of primary unilateral adrenal NK/T cell lymphoma in China with good outcome. CASE PRESENTATION: This is a 28-year-old man who presented with abdominal pain and was found to have a large mass on the left adrenal and the top of the renal region...
January 5, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28024486/-analysis-of-clinical-feature-and-treatment-outcome-of-patients-with-renal-diffuse-large-b-cell-lymphoma
#9
Ping Yang, Hong-Mei Jing, Wei Zhao, Kai Hu, Wei Wan, Lei Tian, Xiao-Yan Ke
OBJECTIVE: To analyse the clinical feature and treatment outcome of patients with renal diffuse large B cell lymphoma(DLBCL). METHODS: The clinical data of 24 patients with renal DLBCL were collected and retrospectively analysed, the clinical features, laboratorial data, survival and prognostic factors were analysed. RESULTS: In our center, the incidence of renal DLBCL was 5.3% in all DLBCL patients, 3 cases were primary renal DLBCL and 21 cases were secondary renal DLBCL, the median age was 52...
December 2016: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/28002527/rare-thymic-malignancy-of-b-cell-origin-t-cell%C3%A3-histiocyte-rich-large-b-cell-lymphoma
#10
Ileana Octavia Petrescu, Iancu Emil Pleşea, Maria Camelia Foarfă, Simona Bondari, Cristina Elena Singer, Elena Mădălina Dumitrescu, Răzvan Cosmin Pană, Georgeta Ligia Stănescu, Mircea Ovidiu Ciobanu
AIM: T-cell÷histiocyte-rich B-cell lymphoma is a rare type of diffuse large B-cell lymphoma reported as involving primarily the thymus only by one paper in the English literature. CASE PRESENTATION: A four and a half years old boy was admitted, after a sudden onset in the middle of the night, with superior vena cava syndrome, resuscitated cardiac and respiratory arrest and severe coma with Glasgow Coma Scale rate of 3. In spite of intensive treatment, the patient repeated twice the cardiac arrest and died sixteen hours after admittance...
2016: Romanian Journal of Morphology and Embryology, Revue Roumaine de Morphologie et Embryologie
https://www.readbyqxmd.com/read/27895762/primary-renal-lymphoma-a-case-report-and-literature-review
#11
Xiaodong Chen, Danfei Hu, Laifu Fang, Yichen Chen, Xiaohang Che, Jin Tao, Guobin Weng, Xiaolei Ye
Primary renal lymphoma (PRL) is a rare disease, with no more than 70 cases reported in the literature. The present study reports the case of a 70-year-old woman with PRL. The patient was asymptomatic, however, a mass on the right kidney was identified incidentally during routine physical examination. Computed tomography revealed a mass in the right kidney that was 3.6 cm in diameter. Subsequently, right nephrectomy was performed. The histological evaluation of the nephrectomy specimen showed diffuse large B-cell non-Hodgkin's lymphoma...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27889778/primary-intestinal-hodgkin-lymphoma-mimicking-intraabdominal-abscess-in-a-renal-transplant-recipient-a-case-report
#12
Biljana Mihaljevic, Darko Antic, Vojin Vukovic, Maja Perunicic Jovanovic, Visnja Lezaic, Nemanja Zaric, Mirko Kerkez, Vladimir Djordjevic
INTRODUCTION: Post-transplant lymphoproliferative disease (PTLD) comprises a variety of lymphoid and plasma cell disorders arising in patients with a solid organ transplant. Monomorphic lymphomas represent the most significant part of this wide spectrum, with the overall risk rising with the aggressiveness of lymphoid proliferation in comparison to the general population. The development of Hodgkin lymphoma is very rare in transplant recipients, comprising less than 6% of all monomorphic PTLD, while cases of primary intestinal Hodgkin lymphoma in these circumstances are anecdotal...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27857838/hyponatraemia-secondary-to-nivolumab-induced-primary-adrenal-failure
#13
Harris Trainer, Paul Hulse, Claire E Higham, Peter Trainer, Paul Lorigan
Checkpoint inhibitors, such as ipilimumab and pembrolizumab, have transformed the prognosis for patients with advanced malignant melanoma and squamous non-small-cell lung cancer, and their use will only expand as experience is gained in a variety of other malignancies, for instance, renal and lymphoma. As the use of checkpoint inhibitors increases, so too will the incidence of their unique side effects, termed immune-related adverse events (irAEs), which can affect dermatological, gastrointestinal, hepatic, endocrine and other systems...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27790565/primary-renal-lymphoma-a-case-report-and-review-of-literature
#14
Shraddha Shetty, Avinash Chandra Singh, Vinod Babu
Primary Renal Lymphoma (PRL) is rare and its existence has been called into question due to the absence of lymphatic tissue within renal parenchyma. Non-specific abdominal pain with mass in the lumbar region and otherwise unexplained renal failure is the most common presentation. Almost all patients eventually develop extrarenal lymphomatous disease and few patients survive beyond one year. Surgical treatment is rarely feasible as primary modality of treatment since the tumour often encases major vessels and surrounding organs necessitating major resection...
September 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/27737327/the-coexistence-of-hypercalcemia-and-hypoglycemia-in-a-patient-with-a-renal-tumor-and-b-cell-lymphoma
#15
Jimena Soutelo, Sofía Moldes, Cielo Frisone, Laura Salvá, Cecilia Agostinis, Gabriel Faraj
Paraneoplastic syndromes are a heterogeneous group of malignant diseases caused by events which involve endocrine, immune and metabolic aspects and whose symptoms vary according to the substance produced and the primary tumor. Hypercalcemia is a frequent complication in cancer patients. Prognosis of cancer patients with hypercalcemia is usually poor. A factor called parathyroid hormone related peptide, whose actions are similar to those of the parathyroid hormone, is thought to be the most common cause of malignancy associated hypercalcemia...
January 2017: Archives of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27667773/an-analytical-comparison-of-dako-28-8-pharmdx-assay-and-an-e1l3n-laboratory-developed-test-in-the-immunohistochemical-detection-of-programmed-death-ligand-1
#16
John Cogswell, H David Inzunza, Qiuyan Wu, John N Feder, Gabe Mintier, James Novotny, Diana M Cardona
AIM: Nivolumab, a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has activity in melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), and Hodgkin lymphoma. Nivolumab is approved in the USA and EU for advanced melanoma, NSCLC, and RCC, and relapsed Hodgkin lymphoma in the USA. Programmed death-ligand 1 (PD-L1), a PD-1 ligand, is expressed on mononuclear leukocytes, myeloid cells, and tumor cells. PD-L1 is being investigated as a potential biomarker to predict the association of tumor PD-L1 expression with nivolumab efficacy...
February 2017: Molecular Diagnosis & Therapy
https://www.readbyqxmd.com/read/27639272/lhrh-receptor-expression-in-sarcomas-of-bone-and-soft-tissue
#17
Chenthuran Deivaraju, H Thomas Temple, Norman Block, Philip Robinson, Andrew V Schally
AIM: Luteinizing hormone releasing hormone (LHRH) is a neurohormone, secreted by the hypothalamus, which regulates the secretion of gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the pituitary. LHRH acts by binding to receptors located in the pituitary gland. These receptors (LHRH receptors) have also been found in the cytoplasm of many tumor cells that involve both the reproductive and non-reproductive organs. These receptors have been demonstrated in prostate and breast cancers, endometrial carcinomas, renal cell carcinoma, lymphoma, carcinoma of liver, pancreas and skin...
November 1, 2016: Hormone Molecular Biology and Clinical Investigation
https://www.readbyqxmd.com/read/27637985/ibrutinib-for-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukaemia-with-17p-deletion-resonate-17-a-phase-2-open-label-multicentre-study
#18
Susan O'Brien, Jeffrey A Jones, Steven E Coutre, Anthony R Mato, Peter Hillmen, Constantine Tam, Anders Österborg, Tanya Siddiqi, Michael J Thirman, Richard R Furman, Osman Ilhan, Michael J Keating, Timothy G Call, Jennifer R Brown, Michelle Stevens-Brogan, Yunfeng Li, Fong Clow, Danelle F James, Alvina D Chu, Michael Hallek, Stephan Stilgenbauer
BACKGROUND: The TP53 gene, encoding tumour suppressor protein p53, is located on the short arm of chromosome 17 (17p). Patients with 17p deletion (del17p) chronic lymphocytic leukaemia have poor responses and survival after chemoimmunotherapy. We assessed the activity and safety of ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, in relapsed or refractory patients with del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma. METHODS: We did a multicentre, international, open-label, single-arm study at 40 sites in the USA, Canada, Europe, Australia, and New Zealand...
October 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27624700/new-risk-factors-and-new-tendency-for-central-nervous-system-relapse-in-patients-with-diffuse-large-b-cell-lymphoma-a-retrospective-study
#19
Qing-Qing Cai, Li-Yang Hu, Qi-Rong Geng, Jie Chen, Zhen-Hai Lu, Hui-Lan Rao, Qing Liu, Wen-Qi Jiang, Hui-Qiang Huang, Tong-Yu Lin, Zhong-Jun Xia
BACKGROUND: In patients with diffuse large B-cell lymphoma (DLBCL), central nervous system (CNS) relapse is uncommon but is nearly always fatal. This study aimed to determine the risk factors for CNS relapse in DLBCL patients and to evaluate the efficacy of rituximab and intrathecal chemotherapy prophylaxis for CNS relapse reduction. METHODS: A total of 511 patients with newly diagnosed DLBCL treated at the Sun Yat-sen University Cancer Center between January 2003 and December 2012 were included in the study...
September 13, 2016: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/27588937/vitamin-d-mediated-hypercalcemia-mechanisms-diagnosis-and-treatment
#20
Peter J Tebben, Ravinder J Singh, Rajiv Kumar
Hypercalcemia occurs in up to 4% of the population in association with malignancy, primary hyperparathyroidism, ingestion of excessive calcium and/or vitamin D, ectopic production of 1,25-dihydroxyvitamin D [1,25(OH)2D], and impaired degradation of 1,25(OH)2D. The ingestion of excessive amounts of vitamin D3 (or vitamin D2) results in hypercalcemia and hypercalciuria due to the formation of supraphysiological amounts of 25-hydroxyvitamin D [25(OH)D] that bind to the vitamin D receptor, albeit with lower affinity than the active form of the vitamin, 1,25(OH)2D, and the formation of 5,6-trans 25(OH)D, which binds to the vitamin D receptor more tightly than 25(OH)D...
October 2016: Endocrine Reviews
keyword
keyword
29415
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"